Stryker Corporation (NYSE:SYK)‘s stock had its “hold” rating restated by investment analysts at Needham & Company LLC in a research report issued on Friday.

Several other analysts also recently weighed in on the company. Royal Bank Of Canada restated a “buy” rating and issued a $155.00 price target on shares of Stryker Corporation in a research note on Friday, September 1st. Argus reiterated a “buy” rating and set a $160.00 target price on shares of Stryker Corporation in a research note on Tuesday, August 29th. Zacks Investment Research downgraded Stryker Corporation from a “hold” rating to a “sell” rating in a research note on Monday, October 16th. BMO Capital Markets reiterated a “hold” rating and set a $140.00 target price on shares of Stryker Corporation in a research note on Tuesday, July 11th. Finally, Cowen and Company set a $160.00 target price on Stryker Corporation and gave the company a “buy” rating in a research note on Friday, October 6th. Two investment analysts have rated the stock with a sell rating, ten have given a hold rating and twelve have assigned a buy rating to the company’s stock. Stryker Corporation currently has a consensus rating of “Hold” and a consensus price target of $151.52.

Stryker Corporation (NYSE:SYK) traded up $1.75 during trading on Friday, hitting $156.18. The company had a trading volume of 1,153,984 shares, compared to its average volume of 1,302,000. The company has a market cap of $58,014.32, a PE ratio of 24.57, a P/E/G ratio of 2.44 and a beta of 0.79. The company has a current ratio of 2.37, a quick ratio of 1.61 and a debt-to-equity ratio of 0.63.

Stryker Corporation (NYSE:SYK) last posted its quarterly earnings results on Thursday, October 26th. The medical technology company reported $1.52 earnings per share for the quarter, topping the consensus estimate of $1.50 by $0.02. The company had revenue of $3.01 billion for the quarter, compared to the consensus estimate of $2.97 billion. Stryker Corporation had a return on equity of 24.11% and a net margin of 14.67%. The firm’s quarterly revenue was up 6.1% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.39 EPS. research analysts forecast that Stryker Corporation will post 6.47 EPS for the current year.

COPYRIGHT VIOLATION WARNING: This piece was first published by American Banking News and is the sole property of of American Banking News. If you are reading this piece on another site, it was copied illegally and reposted in violation of international copyright law. The correct version of this piece can be viewed at https://www.americanbankingnews.com/2017/11/03/stryker-corporation-syk-given-hold-rating-at-needham-company-llc.html.

In related news, insider Graham A. Mclean sold 1,124 shares of the firm’s stock in a transaction on Tuesday, August 8th. The stock was sold at an average price of $146.26, for a total value of $164,396.24. Following the transaction, the insider now directly owns 8,983 shares of the company’s stock, valued at approximately $1,313,853.58. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. 7.40% of the stock is owned by corporate insiders.

A number of institutional investors have recently made changes to their positions in SYK. Acrospire Investment Management LLC bought a new position in Stryker Corporation in the 2nd quarter worth $111,000. Bollard Group LLC raised its holdings in Stryker Corporation by 0.4% in the 2nd quarter. Bollard Group LLC now owns 832 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 3 shares during the period. Motco raised its holdings in Stryker Corporation by 50.7% in the 2nd quarter. Motco now owns 826 shares of the medical technology company’s stock worth $115,000 after purchasing an additional 278 shares during the period. Bruderman Asset Management LLC bought a new position in Stryker Corporation in the 2nd quarter worth $150,000. Finally, James Investment Research Inc. bought a new position in Stryker Corporation in the 2nd quarter worth $155,000. 74.00% of the stock is currently owned by institutional investors.

Stryker Corporation Company Profile

Stryker Corporation is a medical technology company. The Company offers a range of medical technologies, including orthopedic, medical and surgical, and neurotechnology and spine products. The Company’s segments include Orthopaedics; MedSurg; Neurotechnology and Spine, and Corporate and Other. The Orthopaedics segment includes reconstructive (hip and knee) and trauma implant systems and other related products.

Analyst Recommendations for Stryker Corporation (NYSE:SYK)

Receive News & Ratings for Stryker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Stryker Corporation and related companies with MarketBeat.com's FREE daily email newsletter.